Placental Aromatase Deficiency: Difference between revisions

Jump to navigation Jump to search
Line 55: Line 55:
*[[Delayed Puberty]]
*[[Delayed Puberty]]
*[[Insulin resistance]]
*[[Insulin resistance]]
*[[Polycystic ovary syndrome]]
*[[Polycystic ovary syndrome]]<ref name="pmid27086564">{{cite journal| author=Akçurin S, Türkkahraman D, Kim WY, Durmaz E, Shin JG, Lee SJ| title=A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans. | journal=J Clin Res Pediatr Endocrinol | year= 2016 | volume= 8 | issue= 2 | pages= 205-10 | pmid=27086564 | doi=10.4274/jcrpe.2761 | pmc=5096477 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27086564  }} </ref>
*Bone disorders such as [[osteoporosis]]
*Bone disorders such as [[osteoporosis]]



Revision as of 12:20, 17 June 2021

WikiDoc Resources for Placental Aromatase Deficiency

Articles

Most recent articles on Placental Aromatase Deficiency

Most cited articles on Placental Aromatase Deficiency

Review articles on Placental Aromatase Deficiency

Articles on Placental Aromatase Deficiency in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Placental Aromatase Deficiency

Images of Placental Aromatase Deficiency

Photos of Placental Aromatase Deficiency

Podcasts & MP3s on Placental Aromatase Deficiency

Videos on Placental Aromatase Deficiency

Evidence Based Medicine

Cochrane Collaboration on Placental Aromatase Deficiency

Bandolier on Placental Aromatase Deficiency

TRIP on Placental Aromatase Deficiency

Clinical Trials

Ongoing Trials on Placental Aromatase Deficiency at Clinical Trials.gov

Trial results on Placental Aromatase Deficiency

Clinical Trials on Placental Aromatase Deficiency at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Placental Aromatase Deficiency

NICE Guidance on Placental Aromatase Deficiency

NHS PRODIGY Guidance

FDA on Placental Aromatase Deficiency

CDC on Placental Aromatase Deficiency

Books

Books on Placental Aromatase Deficiency

News

Placental Aromatase Deficiency in the news

Be alerted to news on Placental Aromatase Deficiency

News trends on Placental Aromatase Deficiency

Commentary

Blogs on Placental Aromatase Deficiency

Definitions

Definitions of Placental Aromatase Deficiency

Patient Resources / Community

Patient resources on Placental Aromatase Deficiency

Discussion groups on Placental Aromatase Deficiency

Patient Handouts on Placental Aromatase Deficiency

Directions to Hospitals Treating Placental Aromatase Deficiency

Risk calculators and risk factors for Placental Aromatase Deficiency

Healthcare Provider Resources

Symptoms of Placental Aromatase Deficiency

Causes & Risk Factors for Placental Aromatase Deficiency

Diagnostic studies for Placental Aromatase Deficiency

Treatment of Placental Aromatase Deficiency

Continuing Medical Education (CME)

CME Programs on Placental Aromatase Deficiency

International

Placental Aromatase Deficiency en Espanol

Placental Aromatase Deficiency en Francais

Business

Placental Aromatase Deficiency in the Marketplace

Patents on Placental Aromatase Deficiency

Experimental / Informatics

List of terms related to Placental Aromatase Deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Aromatase deficiency is an autosomal recessive disorder in which there is a decrease or absence in the level of aromatase in the body which leads to impairment in the conversion of androgens to estrogen. This is due to a genetic mutation in the CYP19A1, a subtype of Cytochrome P450. Patient affected by this disease typically presents with maternal virilization, amenorrhea in puberty in females. Males are rarely affected.

Historical Perspective

  • The evidence of the disease goes back to year 1991, when the first case of aromatase deficiency occurred in 24year old primigravida and the female fetus showed pseudohermaphroditism.[1]
  • The majority of affected individuals were women during the third trimester of pregnancy manifesting with maternal virilization resulting in hirsutism and acne.

Classification

  • There is no established system for the classification of placental aromatase deficiency.

Pathophysiology

Causes

  • CYP19A1 gene mutation primarily causes placental dromatase deficiency and the placenta is not capable of converting androgenic precursors of estrogen to estradiol. Mutations on exons 3,5 and 9 have been reported.[3]
  • Studies suggested that it is more prevalent in consanguineous marriages and both are heterozygous carriers of the mutation.

Differentiating Any Disease from other Diseases

Epidemiology and Demographics

  • The prevalence of placental aromatase deficiency is unknown. [4]
  • There are only few cases that have been described in the literature.
  • First case in male was reported in 1995.[5]

Risk Factors

Screening

  • There is insufficient evidence to recommend routine screening for Placental aromatase deficiency.

Natural History , Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

  • The hallmark of placental aromatase deficiency is maternal virilization. A positive history of hirsutism, deepening of the voice, and cystic acne is suggestive of placental aromatase deficiency.[4][7]

Physical Examination

  • Physical examination of patients with Placental Aromatase Deficiency is usually remarkable for virilization and masculinization in mother during pregnancy, clitoromegaly, and primary amenorrhea in girls during childhood and puberty.
  • Males are usually normal. They may be tall and have reduced bone age.

Laboratory Findings

  • An elevated concentration of serum testosterone and reduced levels of estrogen is diagnostic of placental aromatase deficiency.
  • In aromatase deficient girls, basal and GnRH-stimulated FSH levels are elevated.[4]
  • Urinary levels of androgens are usually normal or elevated.

Electrocardiogram

  • There are no ECG findings associated with placental aromatase deficiency.

X-ray

  • An x-ray may be helpful in the diagnosis of osteoporosis which manifests mainly in males. Findings on an x-ray suggestive of osteoporosis include loss of bone mass, cortical thinning, and minor fractures.

Echocardiography or Ultrasound

CT scan

  • There are no CT scan findings associated with placental aromatase deficiency.

MRI

  • There are no MRI findings associated with placental aromatase deficiency.

Other Imaging Findings

  • There are no other imaging findings associated with placental aromatase deficiency.

Other Diagnostic Studies

  • There are no other diagnostic studies associated with placental aromatase deficiency.

Treatment

Medical Therapy

  • In patients with Aromatase deficiency lifetime hormone replacement therapy is mandatory.
  • Hormone replacement therapy like oral conjugated estrogen may be useful to stimulate pubertal growth spurt, breast development and induce menstruation in females. This may also lead to the resolution of cystic ovaries and promote bone growth.
  • After 14 years of age, the combination oral contraceptive may be used.[4]
  • Treatment options for males include transdermal estradiol that helps in increasing bone mineral density.[7]

Surgery

Primary Prevention

  • There are no established measures for the primary prevention of Placental aromatase deficiency.

Secondary Prevention

Reference

  1. Shozu M, Akasofu K, Harada T, Kubota Y (1991). "A new cause of female pseudohermaphroditism: placental aromatase deficiency". J Clin Endocrinol Metab. 72 (3): 560–6. doi:10.1210/jcem-72-3-560. PMID 1825497.
  2. 2.0 2.1 Akçurin S, Türkkahraman D, Kim WY, Durmaz E, Shin JG, Lee SJ (2016). "A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans". J Clin Res Pediatr Endocrinol. 8 (2): 205–10. doi:10.4274/jcrpe.2761. PMC 5096477. PMID 27086564.
  3. Ludwikowski B, Heger S, Datz N, Richter-Unruh A, González R (2013). "Aromatase deficiency: rare cause of virilization". Eur J Pediatr Surg. 23 (5): 418–22. doi:10.1055/s-0032-1324798. PMID 23093430.
  4. 4.0 4.1 4.2 4.3 Bulun SE (2014). "Aromatase and estrogen receptor α deficiency". Fertil Steril. 101 (2): 323–9. doi:10.1016/j.fertnstert.2013.12.022. PMC 3939057. PMID 24485503.
  5. Baykan EK, Erdoğan M, Özen S, Darcan Ş, Saygılı LF (2013). "Aromatase deficiency, a rare syndrome: case report". J Clin Res Pediatr Endocrinol. 5 (2): 129–32. doi:10.4274/Jcrpe.970. PMC 3701920. PMID 23748068.
  6. Perez-Sepulveda A, Monteiro LJ, Dobierzewska A, España-Perrot PP, Venegas-Araneda P, Guzmán-Rojas AM; et al. (2015). "Placental Aromatase Is Deficient in Placental Ischemia and Preeclampsia". PLoS One. 10 (10): e0139682. doi:10.1371/journal.pone.0139682. PMC 4596497. PMID 26444006.
  7. 7.0 7.1 Zirilli L, Rochira V, Diazzi C, Caffagni G, Carani C (2008). "Human models of aromatase deficiency". J Steroid Biochem Mol Biol. 109 (3–5): 212–8. doi:10.1016/j.jsbmb.2008.03.026. PMID 18448329.
  8. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K (1995). "Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens". J Clin Endocrinol Metab. 80 (12): 3689–98. doi:10.1210/jcem.80.12.8530621. PMID 8530621.